- SCR7
-
- $185.00
-
2026-04-20
- CAS:1533426-72-0
- Purity:
- Supply Ability: 10g
- SCR7
-
- $1.00
-
2019-07-06
- CAS:1533426-72-0
- Min. Order: 1KG
- Purity: 98-100%
- Supply Ability: 1000kg
|
| Product Name: | SCR7 | | Synonyms: | 2,3-Dihydro-5,6-bis[(E)-(phenylmethylene)amino]-2-thioxo-4(1H)-pyrimidinone;5,6-bis((E)-benzylideneamino)-2-mercaptopyrimidin-4-ol;5,6-bis((E)-benzylideneamino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;SCR7;CS-1733;4(1H)-Pyrimidinone, 2,3-dihydro-5,6-bis[(E)-(phenylmethylene)amino]-2-thioxo-;SCR7 USP/EP/BP;5,6-bis[(E)-(phenylmethylidene)amino]-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one | | CAS: | 1533426-72-0 | | MF: | C18H14N4OS | | MW: | 334.39 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1533426-72-0.mol |  |
| Melting point | 206-208°C | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 7.93±0.25(Predicted) | | color | Light Yellow |
| Uses | SCR7 is an anti cancer molecule that selectively inhibits one of the DNA double strand break (DSB) repair pathways, non-homologous end joining (NHEJ). | | in vivo | SCR7 (SCR7 pyrazine; 10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan[1]. | Animal Model: | BALB/c mice injected with breast adenocarcinoma cells[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) | | Result: | Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan.
|
| | IC 50 | DNA Ligase IV; CRISPR/Cas9 |
| | SCR7 Preparation Products And Raw materials |
|